Evidence map›Paper›PMID 30728527›Full record

ArticleGenetics in medicine : official journal of the American College of Medical Genetics2019

Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.

Hiroki Maruyama, Kaori Miyata, Mariko Mikame, Atsumi Taguchi, Chu Guili, Masaru Shimura, Kei Murayama, Takeshi Inoue, Saori Yamamoto, Koichiro Sugimura and 21 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

Hiroki MaruyamaDepartment of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. hirokim@med.niigata-u.ac.jp.
Kaori MiyataSanofi K.K., Sanofi Genzyme Medical Operations, Rare Disease Medical, Medical Science Liaison, Tokyo, Japan.
Mariko MikameDepartment of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Atsumi TaguchiDepartment of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Chu GuiliDepartment of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Masaru ShimuraDepartment of Metabolism, Chiba Children's Hospital, Chiba, Japan.
Kei MurayamaDepartment of Metabolism, Chiba Children's Hospital, Chiba, Japan.
Takeshi InoueDepartment of Pediatrics, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Japan.
Saori YamamotoDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Koichiro SugimuraDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Koichi TamitaNishinomiya Watanabe Cardiovascular Center, Nishinomiya, Japan.
Toshihiro KawasakiNishinomiya Watanabe Cardiovascular Center, Nishinomiya, Japan.
Jun KajiharaDepartment of Cardiology, Fujinomiya City General Hospital, Fujinomiya, Japan.
Akifumi OnishiDepartment of Human Resource Development of Dialysis Therapy for Kidney Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
Hitoshi SugiyamaDepartment of Human Resource Development of Dialysis Therapy for Kidney Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
Teiko SakaiSukoyaka Clinic, Gifu, Japan.
Ichijiro MurataDepartment of Chronic Kidney Disease, Gifu University Graduate School of Medicine, Gifu, Japan.
Takamasa OdaYamaguchi Prefectural Grand Medical Center, Hofu, Japan.
Shigeru ToyodaDepartment of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Japan.
Kenichiro HanawaDepartment of Cardiology, Internal Medicine, Iwaki Kyoritsu General Hospital, Iwaki, Japan.
Takeo FujimuraDepartment of Nephrology, Kashiwazaki General Hospital and Medical Center, Kashiwazaki, Japan.
Shigehisa UraDivision of Neurology, Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan.
Mimiko MatsumuraDepartment of Nephrology, Tokyo Teishin Hospital, Tokyo, Japan.
Hideki TakanoDepartment of Nephrology, Tokyo Teishin Hospital, Tokyo, Japan.
Satoshi YamashitaDepartment of Cardiology, Japanese Red Cross Hamamatsu Hospital, Hamamatsu, Japan.
Gaku MatsukuraDepartment of Cardiology, Japanese Red Cross Hamamatsu Hospital, Hamamatsu, Japan.
Ryushi TazawaDivision of Medical Genetics, Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, Niigata, Japan.
Tsuyoshi ShigaDepartment of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.
Mio EbatoDivision of Cardiology, Showa University Fujigaoka Hospital, Yokohama, Japan.
Hiroshi SatohDivision of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Satoshi IshiiGlyco Pharma Corporation, Oita, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The HTML version of this Article contained errors in Supplementary Figure S2 "Flowchart of the lyso-Gb3 screening and gene analysis in female patients", which have been detailed in the associated Correction.

Identifiers

PMID30728527
PMCPMC7609257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.